Emergency myelopoiesis in solid cancers

dc.contributor.authorAliazis K.
dc.contributor.authorYenyuwadee S.
dc.contributor.authorPhikulsod P.
dc.contributor.authorBoussiotis V.A.
dc.contributor.correspondenceAliazis K.
dc.contributor.otherMahidol University
dc.date.accessioned2024-07-31T18:11:49Z
dc.date.available2024-07-31T18:11:49Z
dc.date.issued2024-01-01
dc.description.abstractCells of the innate and adaptive immune systems are the progeny of haematopoietic stem and progenitor cells (HSPCs). During steady-state myelopoiesis, HSPC undergo differentiation and proliferation but are called to respond directly and acutely to various signals that lead to emergency myelopoiesis, including bone marrow ablation, infections, and sterile inflammation. There is extensive evidence that many solid tumours have the potential to secrete classical myelopoiesis-promoting growth factors and other products able to mimic emergency haematopoiesis, and to aberrantly re-direct myeloid cell development into immunosuppressive cells with tumour promoting properties. Here, we summarize the current literature regarding the effects of solid cancers on HSPCs function and discuss how these effects might shape antitumour responses via a mechanism initiated at a site distal from the tumour microenvironment.
dc.identifier.citationBritish Journal of Haematology (2024)
dc.identifier.doi10.1111/bjh.19656
dc.identifier.eissn13652141
dc.identifier.issn00071048
dc.identifier.pmid39044285
dc.identifier.scopus2-s2.0-85199378508
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/100072
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleEmergency myelopoiesis in solid cancers
dc.typeReview
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85199378508&origin=inward
oaire.citation.titleBritish Journal of Haematology
oairecerif.author.affiliationSiriraj Hospital
oairecerif.author.affiliationBeth Israel Deaconess Medical Center
oairecerif.author.affiliationHarvard Medical School

Files

Collections